BOSULIF bosutinib 100 mg tablet blister pack

Šalis: Australija

kalba: anglų

Šaltinis: Department of Health (Therapeutic Goods Administration)

Veiklioji medžiaga:

bosutinib monohydrate, Quantity: 103.4 mg (Equivalent: bosutinib, Qty 100 mg)

Prieinama:

Pfizer Australia Pty Ltd

INN (Tarptautinis Pavadinimas):

bosutinib monohydrate

Vaisto forma:

Tablet, film coated

Sudėtis:

Excipient Ingredients: poloxamer; croscarmellose sodium; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350

Vartojimo būdas:

Oral

Vienetai pakuotėje:

30, 28

Recepto tipas:

(S4) Prescription Only Medicine

Terapinės indikacijos:

BOSULIF (bosutinib monohydrate) is indicated for the treatment of chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid Ieukaemia (CML) in adult patients previously treated with two or more tyrosine kinase inhibitors

Produkto santrauka:

Visual Identification: Yellow, oval biconvex, film coated tablets debossed with "Pfizer" on one side and "100" on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 48 Months; Container Temperature: Store below 30 degrees Celsius

Autorizacija statusas:

Licence status A

Leidimo data:

2014-04-29